Cerner and Xealth Collaboration: Working to Improve the Healthcare Experience and Empower Patients to Be Active Participants in their Treatment and Well-Being

Collaboration will Bring Digital Health Tools to Clinicians and Patients to Improve the Health Care Experience

August 6, 2020

Xealth, the leader in enabling digital health at scale, and Cerner Corporation (NASDAQ: CERN), a global health care technology company, are working to improve the health care experience and empower patients to be active participants in their treatment and well-being. As part of this agreement, Cerner and LRVHealth have together invested $6 million in Xealth.

At its core, the relationship between Xealth and Cerner aims to give patients their own digital data so they can be more engaged in their treatment plans. The Xealth platform is designed to help clinicians easily integrate, prescribe and monitor digital health tools for patients from one location in the EHR.

Care teams will be able to order solutions directly from the EHR to manage conditions including chronic diseases, behavioral health, maternity care and surgery preparation. Incorporating Xealth into Cerner’s technology and patient portal will provide easier access to personal health information and give care teams the ability to monitor patient engagement with the tools, as well as analyze the effects of increased engagement on the patient’s health care and recovery.

During the recent surge of COVID-19 across the world, tools that automate patient education, deliver virtual care, support telehealth and offer remote patient monitoring have become even more prominent, creating new methods to inform care decisions and keep care teams and patients connected.

“Today, we have the unique opportunity to improve people’s lives by allowing active participation in their own treatment plans,” said David Bradshaw, Senior Vice President, Consumer and Employer Solutions, Cerner. “Patients want greater access to their health information and are motivated to help care teams find the most appropriate road to recovery. Xealth and Cerner hope to make it easier and more convenient for patients and clinicians to accelerate health care in a more consumer-centric experience.”

The collaboration between Cerner and Xealth will provide care teams and patients convenience and help improve care accessibility. Better communications and engagement between patients and key members of their care team will create an experience that is connected across settings before, during and after a care encounter. Xealth powers more than 30 digital health solutions, connecting patients with educational content, remote patient monitoring, virtual care platforms, e-commerce product recommendations and other services needed to improve health outcomes.

“In order for digital health to have lasting impact, it needs to show value and ease for both the care team and patient,” said Mike McSherry, CEO and Co-Founder of Xealth. “We strongly believe that technology should nurture deeper patient-provider relationships and facilitate information sharing across systems and the care settings. It is exciting to work with Cerner to simplify meaningful digital health for its health partners.”

Cerner and LRVHealth join Xealth investors Atrium Health, Cleveland Clinic, Froedtert and the Medical College of Wisconsin, MemorialCare Innovation Fund, Providence Ventures and UPMC as well as Threshold Ventures, McKesson, Novartis, Philips, and ResMed.

“Combining our expertise in developing interactive digital solutions that improve the patient experience with Cerner’s world-class platforms creates immense opportunity for our clients to better meet the needs of today’s highly connected health care consumer,” concluded McSherry.

SourceXealth
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version